Statistics for Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.

Total visits

views
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. 14

Total visits per month

views
November 2023 0
December 2023 0
January 2024 0
February 2024 0
March 2024 0
April 2024 0
May 2024 0

Top country views

views
United States 9
China 3
Thailand 2

Top city views

views
Roanoke 5
Spring Hope 3
Phitsanulok 2
Chaohu 1
Hangzhou 1
Hongkou 1